In contrast to other therapies approved for SMA treatment, nusinersen, and risdiplam, which alter the splicing of SMN2 gene, onasemnogene abeparvovec is designed to deliver a full-length functional copy of the human SMN1 gene. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.